BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31264434)

  • 1. Evolving Role of Genomics in Genitourinary Neoplasms.
    Devitt ME; Dreicer R
    Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical Molecular Testing in a Clinical Genitourinary Service.
    Magers MJ; Cheng L
    Arch Pathol Lab Med; 2020 Mar; 144(3):277-289. PubMed ID: 31373513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
    Yang Y; Zhang G; Hu C; Luo W; Jiang H; Liu S; Yang H
    BMC Urol; 2022 Nov; 22(1):196. PubMed ID: 36451132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immunotherapy combinations for genitourinary cancers.
    Al Harthy M; Redman J; Madan RA
    Expert Opin Biol Ther; 2020 Mar; 20(3):253-262. PubMed ID: 31914333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Sequencing Should Not be Part of the Standard of Care for Most Urologic Cancers.
    Abern MR; Dudinec JV; Inman BA
    Eur Urol Focus; 2022 May; 8(3):639-640. PubMed ID: 35537938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of advanced genitourinary tumors.
    Pietrantonio F; Biondani P; Verzoni E; Procopio G
    Tumori; 2012; 98(2):264-6. PubMed ID: 22677995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy.
    Bergerot CD; Bergerot PG; Philip EJ; Hsu JA; Dizman N; Vaishampayan U; Dorff T; Pal SK
    J Immunother Cancer; 2019 Mar; 7(1):71. PubMed ID: 30867071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
    Nickerson ML; Witte N; Im KM; Turan S; Owens C; Misner K; Tsang SX; Cai Z; Wu S; Dean M; Costello JC; Theodorescu D
    Oncogene; 2017 Jan; 36(1):35-46. PubMed ID: 27270441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments.
    Schmidt AL; Siefker-Radtke A; McConkey D; McGregor B
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-11. PubMed ID: 32379987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genitourinary malignancies.
    Michaelson MD; Smith MR
    Cancer Chemother Biol Response Modif; 2003; 21():547-64. PubMed ID: 15338763
    [No Abstract]   [Full Text] [Related]  

  • 12. Adaptive Immunity in Genitourinary Cancers.
    Koti M; Bivalacqua T; Black PC; Cathomen T; Galsky MD; Gulley JL; Ingersoll MA; Kamat AM; Kassouf W; Siemens DR; Gao J
    Eur Urol Oncol; 2023 Jun; 6(3):263-272. PubMed ID: 37069029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
    González Del Alba A; Arranz JÁ; Puente J; Méndez-Vidal MJ; Gallardo E; Grande E; Pérez-Valderrama B; González-Billalabeitia E; Lázaro-Quintela M; Pinto Á; Lainez N; Piulats JM; Esteban E; Maroto Rey JP; García JA; Suárez C
    Crit Rev Oncol Hematol; 2017 May; 113():171-190. PubMed ID: 28427506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biennial report on genitourinary cancers.
    Fizazi K
    Eur J Cancer; 2016 Oct; 66():125-30. PubMed ID: 27569040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.
    Alsidawi S; Kasi PM
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib in genitourinary malignancies.
    Zhang T; Park SE; Hong C; George DJ
    Future Oncol; 2017 Apr; 13(8):755-765. PubMed ID: 27842445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
    Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genitourinary cancer.
    Hudes GR; Ozols RF; Schilder RJ
    Cancer Chemother Biol Response Modif; 1991; 12():509-48. PubMed ID: 1718377
    [No Abstract]   [Full Text] [Related]  

  • 19. Present and future of personalized medicine in adult genitourinary tumors.
    Ciccarese C; Santoni M; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Conti A; Tortora G; Cascinu S; Montironi R
    Future Oncol; 2015; 11(9):1381-8. PubMed ID: 25952784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.
    Marciscano AE; Madan RA
    Curr Treat Options Oncol; 2018 Mar; 19(3):16. PubMed ID: 29520448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.